Long-term results of breast-conserving treatment for early-stage breast cancer in Japanese women from multicenter investigation

Japanese Journal of Clinical Oncology

Volumn 33, Issue 2, 2003, Pages 61-67

  Ohsumi, Shozo ^a   Sakamoto, Goi ^b   Takashima, Shigemitsu ^a   Koyama, Hiroki ^c   Shin, Eisei ^d   Suemasu, Kimito ^e   Nishi, Tsunehiro ^f   Nakamura, Seigo ^g   Iino, Yuichi ^h   Iwase, Takuji ⁱ   Ikeda, Tadashi ^j   Teramoto, Seiichi ^k   Fukutomi, Takashi ^l   Komaki, Kansei ^m   Sano, Muneaki ⁿ   Sugiyama, Kazuyoshi ^o   Miyoshi, Kazuya ^p   Kamio, Takako ^q   Ogita, Masami ^r  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b CANCER INSTITUTE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f MITSUI MEMORIAL HOSPITAL   (Japan)

^g ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^h GUNMA UNIVERSITY   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER   (Japan)

^l NATIONAL CANCER CENTER HOSPITAL   (Japan)

^m UNIVERSITY OF TOKUSHIMA   (Japan)

ⁿ NIIGATA CANCER CENTER HOSPITAL   (Japan)

^o JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p Fukuyama National Hospital   (Japan)

^q TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^r HOKKAIDO CANCER CENTER   (Japan)

more..

Author keywords

Adjuvant endocrine therapy; Breast cancer; Breast conserving treatment; Predictive factor; Prognostic factor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; EXPERIMENTAL DESIGN; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; JAPAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SEGMENTAL MASTECTOMY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TAMOXIFEN;

EID: 0037316689     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg014     Document Type: Article

References (24)

1. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, Andersen KW, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 1992;11:19-25.
2. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
3. Lichter AS, Lippman ME, Danforth DN, d'Angelo T, Steinberg SM, deMoss E, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: A randomized trial at the National Cancer Institute. J Clin Oncol 1992;10:976-83.
4. Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989; 14:177-84.
5. van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer. EORTC 10801 trial. J Natl Cancer Inst Monogr 1992;11:15-8.
6. Veronesi U, Banfi A, Del Vecchio M, Saccozzi R, Clemente C, Greco M, et al. Comparison of Halsted mastectomy with quadrantectomy, axillary dissection and radiotherapy in early breast cancer: Long-term results. Eur J Cancer Clin Oncol 1986;22:1085-9.
7. Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durand J-C, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17: 719-25.
8. Fowble BL, Solin LJ, Schultz DJ, Goodman RL. Ten year results of conservative surgery and irradiation for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1991;21:269-77.
9. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 1991;21:293-8.
10. Kurtz JM, Amalric R, Brandone H, Ayme Y, Jacquemier J, Pietra J-C, et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course and prognosis. Cancer 1989;63:1912-7.
11. Recht A, Silen W, Schnitt SJ, Connolly JL, Gelman RS, Rose MA, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys 1988;15:255-61.
12. Heimann R, Powers C, Halpern HJ, Michel AG, Ewing CA, Wyman B, et al. Breast preservation in stage I and II carcinoma of the breast. The University of Chicago experience. Cancer 1996;78:1722-30.
13. Yonemoto RH. Breast cancer in Japan and the United States. Arch Surg 1980;115:1056-62.
14. Anscher MS, Jones P, Prosnitz LR, Blackstock W, Herbert M, Reddick R, et al. Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg 1993; 218:22-8.
15. Locker AP, Ellis IO, Morgan DAL, Elston CW, Mitchell A, Blamey RW. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg 1989;76:890-4.
16. Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, Dura RB, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994;74:1746-51.
17. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990;8:591-8.
18. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
19. Inaji H, Koyama H, Motomura K, Noguchi S, Tsuji N, Wada A. Immunohistochemical survey of pS2 expression in intraductal lesions associated with invasive ductal carcinoma of the breast. Int J Cancer 1993;55:883-6.
20. Yamakawa T, Morimoto T, Sasa M, Numoto S, Monden Y. High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer. Jpn J Cancer Res 1995;86:1035-40.
21. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351: 1451-67.
23. Whelan T, Clark R, Roberts R, Levine M, Foster G. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Int J Radiat Oncol Biol Phys 1994;30: 11-6.
24. Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991;338:327-31.